Morningstar

Rigaku BioScience Lab Opens in USA

Rigaku has begun operation of MoleQlyze at the Rigaku BioScience Lab. MoleQlyze incorporates a technology, developed by Rigaku, called electron density topography (EDT), which elucidates the structure ...
Business Wire

Canyon Labs Announces Strategic Acquisition of iuvo BioScience’s Lab Services and Consulting Businesses to Expand End-to-End Development Solutions

SALT LAKE CITY & ROCHESTER, N.Y.--(BUSINESS WIRE)--Canyon Labs, a global leader in analytical & packaging lab testing and consulting for medical devices and pharmaceuticals, and iuvo BioScience, a ...
Seeking Alpha

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

Elevai Labs (ELAB) established two subsidiaries: Elevai Biosciences, Inc., and Elevai Skincare, Inc. Elevai Biosciences will focus on acquiring and developing biopharmaceutical technologies with ...
GEN

Multiply Labs and Retro Biosciences Partner on Cell Therapy Manufacturing for Age-Related Diseases

Multiply Labs, a robotics firm, and Retro Biosciences, which is developing therapies to address age-related diseases, signed an agreement valued at up to $85 million to automate Retro’s approach to ...
Healio

VIDEO: Canyon Labs’ acquisition of iuvo Bioscience will help drive ophthalmic research

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Ben Burton of iuvo Bioscience sheds ...
Seeking Alpha

Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products

NEWPORT BEACH, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (ELAB) a medical aesthetic company specializing in physician-dispensed skincare, today announced that they have signed a ...
Business Insider

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the ...

EL-22 is a novel myostatin asset for the potential treatment of obesity in combination with existing GLP-1 medicines The Investigational New Drug application is planned for submission to the U.S. Food ...
Business Insider

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP ...

Filed two patent applications for lead candidate EL-22, covering muscle loss in obese patients as a monotherapy and in combination with GLP-1 receptor agonists Elevai Biosciences patent portfolio now ...
Eagle-Tribune

Maine Mobile Bioscience Lab to Launch in Early 2024 for Maine Middle Schools | Region | eagletribune.com

Initiative Will Build Awareness of Maine Bioscience Careers through Traveling Program PORTLAND, Maine, Sept. 20, 2023 /PRNewswire/ -- Portland-based nonprofit organization Educate Maine, in ...
Nasdaq

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the ...

Preclinical results of EL-32 demonstrated statistically significant increases in grip strength, motor function and body composition in aged C57BL/6J mouse model. Elevai believes that EL-32 has the ...
AFP

Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale

Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a collaboration with Codebreaker Labs to develop and validate a breakthrough ...